Vimseltinib

Overview

Vimseltinib (DCC-3014) is a c-FMS ( CSF-IR ) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC 50 s of <0.01 μM and 0.1-1 μM, respectively. Vimseltinib has certain oral bioavailability.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > c-Fms | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-136256
• CAS No.: 1628606-05-2
• Molecular Formula: C23H25N7O2
• Molecular Weight: 431.49
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution
• Availability: In-stock

Source

Original product source